Search results
Showing 1951 to 2000 of 2053 results for work
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
KardiaMobile recommended for people having antipsychotic medication
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone-linked ECG device
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
NICE welcomes Dr Michael Borowitz as new NICE non-executive director
New NICE non-executive director appointment approved by the Secretary of State for Health and Social Care
Routine funding recommended for Duchenne muscular dystrophy gene therapy ataluren
NICE has today published final guidance which recommends ataluren (also called Translarna and made by PTC Therapeutics) for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation.
NICE recommends offering PrEP to people at high risk of HIV for first time
People at the highest risk of catching HIV should be offered Pre Exposure Prophylaxis (PrEP), NICE has recommended for the first time.
NICE recommends range of treatments for people with chronic primary pain
People with chronic primary pain should be offered a range of treatments to help them manage their condition.
Artificial intelligence to speed up contouring in radiotherapy treatment planning
Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers
NICE recommended treatment for Parkinson's set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
Hundreds of people with some forms of urothelial cancer to receive new treatment
People with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment – avelumab – following its recommendation for funding
Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes
NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.
Innovative technology to detect abnormal heart rhythms recommended by NICE
Zio XT is the first assessment, via the NICE digital health technologies guidance development pilot project, to be recommended for NHS use.
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life.
A safe space for bold ideas – implementing a sandbox approach in health technology assessment
Colleagues in our Science Policy and Research Programme discuss their international research, paving the way for next generation health technology assessment.
Lead with confidence through our Executive MSc in Healthcare Decision-Making.
Introducing CHEERS-AI: improving health economic evaluation reporting for AI technologies
Our contribution to world-leading research.
Your voice is needed – my experience as a NICE committee member
Dr Raja discusses the vital role frontline NHS colleagues have on our independent committees, and how you can get involved.
NICE provides access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
Around 400 people with advanced breast cancer are set to benefit from a new treatment
Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
NICE is getting ready for the end of the transition period after Brexit
NICE has a key role in ensuring the UK remains a destination of choice for the life sciences sector.
NICE outlines steps needed to put ME/CFS guideline into practice
NICE has today, (Thursday, 12 May 2022) published its implementation statement for its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)
Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated into NICE’s new combined methods and processes manual and topic selection manual published today (31 January 2022).
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
Over 700 people a year could benefit from a new lung cancer drug
An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).
Women should be offered induced labour earlier than previously advised
Induced labour should be offered earlier than previously advised to make birth safer for women and their babies, according to draft guidelines published by NICE today (25 May 2021). The updated recommendations strengthen previous advice in the light of new evidence on induction timings.
Speaking with one language: How using a common data model might speed up decision making
The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.
We have also recommended osimertinib for routine use on the NHS today.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
New price deal paves way for NICE approval of treatment for rare genetic condition
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%
Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.
Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in urgent care settings.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.
Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Thousands could benefit from new option for treating symptoms of uterine fibroids
As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
People who have had a stroke should be offered additional rehabilitation
People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover
Three treatments for COVID-19 recommended in final draft guidance
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.
NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.
Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.
NICE partners with international health technology assessment bodies
Six health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.
Hundreds of children with type 2 diabetes to be offered choice of two life changing technologies
Children with type 2 diabetes who currently manage their condition with the stressful task of finger prick testing several times a day could be offered a choice between two ‘life changing’ technologies to virtually automate the process.
NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.